Journal of Inherited Metabolic Disease

, Volume 26, Issue 8, pp 729–744 | Cite as

Neonatal screening for cystic fibrosis: France rises to the challenge

  • J. P. Farriaux
  • M. Vidailhet
  • M. L. Briard
  • V. Belot
  • J. L. Dhondt
Article

Abstract

Summary: This paper describes the adjustments to the French neonatal screening programme required by the introduction of systematic screening for cystic fibrosis (CF), taking into account both the legal and statutory framework and the lessons of a pilot study carried out 10 years ago. The French association for the screening and prevention of infant handicaps (AFDPHE) has been mandated by its regulatory agencies to organize screening for CF in France (metropolitan and overseas territories). During the year 2001, expert groups (Technical Aspects, Information, Ethics and Genetics, Criteria for CF Centres, Protocol for the Care of a Newborn with CF) issued recommendations for the establishment of a national programme that would guarantee efficiency and adequate patient care from the time of diagnosis onward. The programme is based on a strategy combining immunoreactive trypsin (IRT) assay and the analysis of DNA mutations in dried blood samples obtained at 3 days of age. When an elevated IRT value is found, DNA analysis is performed on the same sample. Owing to the relative regional heterogeneity existing in France, 30 selected mutations are used, which provide 85% coverage. The Ethics and Genetics Committee recommended that, in order to avoid arousing anxiety by a recall, informed consent, according to the French legislation on bioethics, should be obtained for all neonates at birth by having the parents sign directly on the sampling paper. Information brochures for parents and health professionals have been designed. A new organization of patient care, involving the creation of CF centres recognized by the Ministry of Health, has been decided; all children diagnosed are to be referred to such centres, where they can be well cared for by a trained staff with sufficient means. The programme was implemented region by region in France, from the beginning of the year 2002 to early 2003. The expert groups still meet periodically to evaluate the implementation of the programme and to check that the terms of the agreement between the AFDPHE and the Social Security Agency are complied with.

Keywords

Cystic Fibrosis Cystic Fibrosis Patient Congenital Adrenal Hyperplasia Neonatal Screening Sweat Test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. Al-Jader LN, Goodchild MC, Ryley HC, Harper PS (1990) Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 38: 460-465. PubMedCrossRefGoogle Scholar
  2. Corbetta C, Seia M, Bassotti A, Ambrosioni A, Giunta A, Padoan R (2002) Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population. J Med Screen 9: 60–63.PubMedCrossRefGoogle Scholar
  3. Dhondt JL, Farriaux JP (1997) Impact of French legislation on neonatal screening. In Knoppers BM, ed. Human DNA: Law and Policy. The Hague: Kluwer Law International, 285–289.Google Scholar
  4. Dhondt JL, Farriaux JP, Briard ML, Boschetti R, Frézal J (1993a) Results of pilot screening activities in the French neonatal screening program cystic fibrosis, congenital adrenal hyperplasia and sickle cell disease. Screening 2: 87–89.CrossRefGoogle Scholar
  5. Dhondt JL, Farriaux JP, Briard ML, Boschetti R, Frézal J (1993b) Neonatal screening in France. Screening 2: 77-85. CrossRefGoogle Scholar
  6. Duchassaing D, Dingeon B, Chalas J, Coude M, Coulhon M-P, Launay J-M (2002) Gentique mol6culaire: les 'bonnes pratiques' pré-et postanalytiques. Ann Biol Clin 60: 617–621.Google Scholar
  7. Feldmann D, Guittard C, Des Georges M, et al (2001) Diagnostic molculaire de la mucoviscidose: valuation de la trousse Elucigene® CF20 dans le sang et les cellules buccales. Ann Biol Clin 59: 277–283.Google Scholar
  8. Ferec C, Verlingue C, Parent P, et al (1995) Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses. Hum Genet 96: 542-548. PubMedGoogle Scholar
  9. Newton CR, Graham A, Heptinstall IE, et al (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 17: 2503-2516. PubMedGoogle Scholar
  10. Pollitt RJ, Green A, McCabe CJ, et al (1997) Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technology Assessment 1(7) (http: / /www.ncchta.org).Google Scholar
  11. Ranieri E, Ryall RG, Morris CP, et al (1991) Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis. Br Med J 302: 1237–1240.CrossRefGoogle Scholar
  12. Tluczek A, Mischler EH, Farrell PM, et al (1992) Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 13: 181–186.PubMedGoogle Scholar
  13. Wilcken B, Chalmers GR (1985) Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet 2: 1319–1321.PubMedCrossRefGoogle Scholar
  14. Wilson JMG, Jungner G (1968) Principles of Screening for Disease. Geneva: World Health Organization, 26–39.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • J. P. Farriaux
    • 1
  • M. Vidailhet
    • 1
  • M. L. Briard
    • 1
  • V. Belot
    • 1
  • J. L. Dhondt
    • 1
    • 2
  1. 1.Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant (AFDPHE)ParisFrance
  2. 2.LaboratoireHôpital St PhilibertLomme cedexFrance

Personalised recommendations